ClearPoint Neuro Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while iShares 0 3 Month Treasury Bond ETF trades at $100.53. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | SGOV | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | Fixed Income |
52-Week High | $29.60 | $100.74 |
52-Week Low | $8.66 | $100.28 |
Enterprise Value | $506.63M | — |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% on the day. The technical outlook is bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights strong inflows into cash ETFs amid market volatility and Federal Reserve uncertainty. The fund offers a low-risk haven with a 0.09% expense ratio and yields around 3.54–3.65%, attracting income-focused investors.
The outlook for SGOV is stable, providing a secure parking spot for cash with minimal interest rate risk due to its short duration. Investment opportunity lies in capital preservation and competitive yield versus savings accounts. Primary risks include potential Fed rate cuts reducing yields and high investor concentration in cash-like assets if equity markets rally. The fund suits conservative portfolios seeking liquidity and safety.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →